ADC drug discovery is influenced by multiple factors, such as internalization, stability, tumor heterogeneity, pharmacokinetics (PK), and safety. This white paper introduces integrated in vitro and in vivo strategies for ADC characterization and differentiation, discusses key development challenges and approaches to mitigate downstream risks, and highlights context-specific evaluation strategies for next-generation conjugate modalities.
You’ll discover how to:
- Build an in vitro ADC characterization workflow to assess internalization, cytotoxicity, bystander killing, and serum/plasma stability
- Connect in vitro findings with in vivo pharmacology through PK/PD, efficacy, and safety evaluation
- Navigate key development challenges, including complex PK and developability risks, narrow therapeutic window, and drug resistance
- Explore context-specific evaluation strategies for emerging conjugate modalities, such as bispecific ADCs, AOCs, and dual linker-payload ADCs
